UST demonstrated superior 52-week treatment persistence in IBD patients who had previously been treated with VDZ, compared to those treated with anti-TNF agents, suggesting that UST may be a more favorable option for IBD patients who have failed VDZ treatment. The gene discussed is TNF; the disease is inflammatory bowel disease.